Introduction
============

Invasive aspergillosis (IA) is one of the most common life-threatening fungal infections that has emerged as an important cause of morbidity and mortality in immunocom-promised patients that ranges from 70% to 90% in one year \[[@B1]\]. IA is due to ubiquitous *Aspergillus*species that invade from the lungs into the adjacent organs if the immune system is compromised. Recently several reports have revealed a rising incidence of IA in critically ill patients admitted to the intensive care unit (ICU) in otherwise healthy individuals \[[@B2]-[@B5]\]. The occurrence of IA in the ICU usually entails a poor prognosis, despite major recent improvements in the diagnosis and treatment of IA in patients with hematologic diseases \[[@B6]\]. Early diagnosis of IA is very important and requires diagnostic tools validated in the ICU population that show positive results in an early phase of the infection \[[@B7]\]. In IA, the clinical manifestations and symptoms are generally non-speciﬁc, mechanical ventilation makes it difficult to interpret clinical signs, and radiological diagnoses are clouded by underlying lung pathologies \[[@B8]\]. The significance of positive results of culture or positive ﬁndings of a direct microscopic examination of a respiratory specimen is greatly uncertain, because they have low sensitivity (50%) and speciﬁcity (20%--70%), depending on whether the patient is immunocompromised \[[@B9],[@B10]\]. Histopathological examination as the golden standard method is not often practicable because of the patient's status that prohibits invasive procedures \[[@B11]\]. Therefore due to the restrictions of the aforementioned diagnostic tools, a non-culture based method, which can detect a biomarker such as galactomannan (GM) antigen, has been developed. GM is a cell wall polysaccharide component released during growth and invasion of *Aspergillus* in tissue that is detectable in patients with invasive aspergillosis \[[@B12]\]. Studies showed a sensitivity of 61% to 71%, with a specificity of 89% to 93% for the detection of GM in serum samples \[[@B13]\]. Recently, detection of GM in BAL fluid has been considered as a diagnostic approach for IPA by some authors \[[@B14]-[@B16]\]. On the other hand, it has not well established a consensus on optical density (OD) cut-offs in BAL samples by ELISA method for the diagnosis of IA.

According to our search in international databases, there are no available data on GM detection in BAL samples among ICU patients in the Middle East. In the current study, we aimed to assess GM detection in BAL ﬂuid with Platelia *Aspergillus*GM EIA as an early diagnostic tool among ICU patients who were at risk for developing IA.

Material and Methods
====================

***Patients***

The Ethics Committee of Mazandaran University of Medical Sciences (code: 88-6-4) approved this research and the written informed consent was obtained from the patient or next of kin. We reviewed all adult patients suspected to have IA (host factors and clinical features) as defined by European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) \[[@B17]\] who hospitalized in the ICU of the University Hospitals in Mazandaran, Iran from August 2010 to September 2011. BAL samples were collected by pulmonologists twice weekly thereafter if feasible. Patients using piperacillin/tazobactam at the time of bronchoscopy and prolonged use (more than 1 week) of any antifungal drugs were excluded. Briefly, the lobe bronchus in which consolidation was imaged by chest radiograph or chest CT scan was wedged, and 20 to 50 ml of 0.9% sterile saline solution at room temperature was instilled with a syringe through the working channel of the bronchoscope. The total volume of saline solution instilled into the lung was typically 50 ml to 100 ml of BAL fluid was recovered. Subsequently, the obtained BAL fluid was sent directly unprocessed on dry ice to the department of Medical Mycology at Mazandaran University of Medical Sciences, Sari.

***Laboratory work***

A total of sixty six BAL fluid samples were collected. BAL samples were analyzed by direct microscopic examination using CalcoFlour White staining, fungal culture and GM detection. Cultures for fungi were performed by inoculating clinical specimens onto Sabouraud glucose agar at 30˚C for 10 days. The fungi were identified by standard mycological techniques based upon gross cultural and microscopic morphology.

***Platelia Aspergillus ELISA***

The Platelia *Aspergillus*GM EIA (Platelia *Aspergillus*; Bio-Rad, Edmonds, WA) was performed for GM detection according to the manufacturer's instructions. Briefly, 100 µl of the Platelia treatment solution was added to 300 µl of the BAL specimen, which was then heated at 100°C for 3 min, followed by centrifugation at 10,000 *g*for 10 min. Then, 50 µl of the supernatant and 50 µl of the horseradish peroxidase-labeled monoclonal antibody (EBA-2) were incubated at 37°C in antibody-precoated microplates for 90±5 min. The plates were washed 5 times, and then were incubated with 200 µl of substrate chromogen reaction solution for 30±5 min at room temperature in the dark. The reaction was stopped by the use of 100 µl sulfuric acid, and after 30 min, the plates were read at an optical density (OD) of the sample to that of the threshold control samples at 450 nm with a reference filter of 620 nm. An OD index of ≥1.0 in two consecutive samples was considered positive. All positive samples were rechecked and only if the repeat test was also positive they have take into accounted positive.

***Case and definition of positive results***

The Patients with IA were classified as having probable or possible IA on the basis of modified EORTC/MSG criteria \[[@B17]\]. Sensitivity, speciﬁcity, positive predictive value (PPV) and negative predictive value (NPV) were calculated according to the proportion of patients with true and false positive and negative tests. Calculations were also performed based on the certainty of IA.

Results
=======

[Table 1](#T1){ref-type="table"} summarized and characterized the patients who were enrolled in this study. According to modified EORTC/MSG criteria, out of 43 patients, 4 cases (30.8%) were classified as possible IA and 9 (69.2%) as probable IA. In this present study, we were not able to define a proven IA case because there was an explicit refusal of the family to do biopsy or autopsy. Out of 21 BAL samples obtained from 13 patients with probable IA, 76.2% was positive for GM. Of these, 53.8% and 77% of samples had positive results in culture and direct microscopic examination methods, respectively ([Table 2](#T2){ref-type="table"}).

In 6 cases, culture or direct microscopic examination on BAL samples remained negative, whereas GM detection was positive. All patients with IA had at least one positive BAL GM (OD index ≥ 0.5 and \> 1.0). Out of 45 BAL samples from patients without IA, 43 (95.5%) had negative GM results ([Figure 1](#F1){ref-type="fig"}).

[Table 3](#T3){ref-type="table"} shows the sensitivity, speciﬁcity, positive and negative predictive values of different BAL GM index. A cut off ≥ 0.5 yielded a 100% of sensitivity and 96% of negative predictive value (NPV) with relatively low speciﬁcity and positive predictive value (PPV). On the other hand, a cut off \>2 improve of speciﬁcity and PPV.
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###### 

Characteristics of studied patients

  ---------------------------------------------------------------------------------------------------
  Characteristics                 Probable IA\      Possible IA\   Non IA\     All\        
                                  (n=9)             (n=4)          (n=30)      (n=43)      
  ------------------------------- ----------------- -------------- ----------- ----------- ----------
  Mean of age (years)             47.8              62             58.4        56.5        

  Sex, male, (%)                  6 (66.6)          2 (50)         16 (53)     24 (58.8)   

  ICU length of stay (days)       7.3               9.75           25          19.6        

  Mechanical ventilation (days)   6.7               6.25           22          18.2        

  No. of deaths (%)               7 (77.8)          2 (50)         8 (26.7)    16 (37)     

  Underlying disease              Neutropenia (%)   7 (77.8)       0           0           8 (18.6)

  Hematologic (%)                 5 (55.6)          2 (6.7)        2 (6.7)     9 (30)      

  COPD (%)                        1 (11.0)          1 (3.3)        1 (3.3)     3 (7)       

  Solid cancer (%)                2 (22.0)          5 (16.7)       5 (16.7)    8 (18)      

  Diabetes                        0                 5 (16.7)       5 (16.7)    6 (14)      

  Other                           0                 25 (83.3)      25 (83.3)   25 (58)     
  ---------------------------------------------------------------------------------------------------

Deﬁnition of abbreviations: COPD = chronic obstructive pulmonary disease; IA = invasive aspergillosis; ICU =intensive care unit.

###### 

BAL galactomannan, direct examination and culture results in patients

                                            Percentage of patients                 
  ----------------------------------------- ------------------------ ------ ------ ------
  BAL GM^[1](#TFN1){ref-type="table-fn"}^   Positive                 84.6   6.6    30.2
  Negative                                  15.3                     93.3   69.7   
  BAL direct examination                    Positive                 77     36.6   48.8
  Negative                                  23                       63.3   51.1   
  BAL culture                               Positive                 53.8   20     30.2
  Negative                                  46                       80     69.7   

Deﬁnition of abbreviation: BAL= bronchoalveolar lavage; GM = galactomannan.

Cutoff value for positivity: 1.0 ng/ml

###### 

Sensitivity, specificity and predictive values for some selected cutoff GM index of patients with probable and possible IA as a standard (%).

  GM index        Sensitivity   Specificity   PPV    NPV
  --------------- ------------- ------------- ------ ------
  **≥0.5**        100           85.7          65.7   96
  **≥1.0**        73            92.7          89     87.3
  **≤** **1.5**   66            96.8          94     87
  **≤** **2.0**   64            98            96     85

Deﬁnition of abbreviation: PPV= positive predictive value; NPV= negative predictive value; GM = galactomannan

Discussion
==========

Detections of GM in BAL samples can be consider as a method, which facilitate the early diagnosis of invasive aspergillosis-a life threatening disease in immunocompromised patients. In spite of several disadvantages, BAL or serum GM detection remains a powerful technique in the diagnosis and management of patients at high risk of invasive aspergillosis \[[@B18]\]. To our knowledge, this is the first study to evaluate the utility of measuring BAL galactomannan in ICU patients in Iran. Recently, several prospective studies in ICU patients reported sensitivities, speciﬁcities and predictive values above 90% for GM detection in BAL samples \[[@B4], [@B14], [@B19]\]. Our results indicated that BAL GM detection with higher sensitivity (100 %) and specificity (85.7 %) at a cutoff ≥ 0.5 compared to conventional methods for the diagnosis of IPA in at-risk patients in ICU. This observation is similar to those described by previous studies \[[@B14], [@B19]\]. The high sensitivity of GM detection in the BAL may reduce the speciﬁcity due to false positive results. However, many sources of false positivity including piperacillin -- tazobactam or amoxicillin -- clavulanate are frequently and remarkably encountered in the ICU \[[@B20]\], the speciﬁcity was still above 85%. In our study, BAL GM detection was performed early, promptly after CT and before the start of antifungal treatment. Verweij et al, and Salonen et al, suggested that antifungal therapy can explain the somewhat lower sensitivities of GM detection in BAL ﬂuid \[[@B21], [@B22]\].

Our study had several limitations; rare case of IA and small sample size which may have limited our power to detect differences between the groups, bronchoscopy procedures is not usually performed in the evaluation of IA in ICU patients due to the critical conditions of patients, and unless with abnormal respiratory signs at CT finding and autopsy process from patients suspected IA, has not been reported cases of proven IA. Moreover, OD measurements are dependent on the concentration of GM antigen, which being dependent on several factors such as the area that is washed, the amount of saline instilled during bronchoscopy procedure, and the amount of fluid retrieved. In our study, instilled either 20 or 50 ml each time, this difference may add variability to the results. The amount of sterile saline instilled varied significantly (40 to 150 ml) between studies \[[@B15], [@B16], [@B23], [@B24]\] suggesting that the results although similar may not be comparable or extrapolated to other centers. Therefore, a standardized method of collection should also be established before results can be comparable between centers. Finally, we cannot provide data on the inﬂuence of antifungal therapy on the performance of GM detection in BAL ﬂuid.

Conclusion
==========

Since the diagnosis of IA is a big challenge, early diagnosis is crucially important because early antifungal therapy improves surviva1. Our data have revealed that the sensitivity of GM detection in BAL was better than that of conventional tests. It seems that GM detection in BAL is beneficial to establish or exclude of early diagnosis of IA in ICU patients. Therefore, a prospective screening of BAL GM is an essential role for early diagnosis of IA, especially when it is combined with other diagnostic tools. The validity of the data needs to be conﬁrmed in other ICUs and examine various aspects in ICU Patients.
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